Imvax Presents Promising Results from IGV-001 Phase 1b Study for Glioblastoma at SNO Annual Meeting
PHILADELPHIA, PA — Imvax, Inc., a clinical-stage biotechnology company, recently announced details of its two poster presentations at the 2023 Society for NeuroOncology (SNO) 28th Annual Meeting. The event was …
Imvax Presents Promising Results from IGV-001 Phase 1b Study for Glioblastoma at SNO Annual Meeting Read More